MSN Laboratories Pvt. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MSN Laboratories Pvt. Ltd.
Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?
India’s MSN Labs has kicked off the year by launching four recently-approved generics in the US through affiliate Novadoz, including albendazole, droxidopa, deferasirox and pregabalin. The company says it is preparing a “deep pipeline” of launches for the next 10 years.
India’s MSN Laboratories is set to move on a generic version of RedHill Biopharma’s Movantik (naloxegol oxalate) for opioid-induced constipation ahead of patent expiry under the terms of a patent-litigation settlement agreement.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.
- Generic Drugs